Lipids & Metabolic

The U.S. FDA this month granted Fast Track designation to AstraZeneca for the development of Farxiga, or dapagliflozin. 

SGLT2 inhibitors—namely dapagliflozin—have been linked to a reduced risk of heart failure and death, as well as decreased odds of major adverse cardiovascular events.

A multi-country study in Asia has revealed patients with both type 2 diabetes and heart failure face higher odds of structural CV abnormalities, a poorer quality of life and an increased risk of death.

An August 19 science advisory from the AHA states that a 4-gram dose of prescription omega-3 fatty acid medication can greatly reduce people’s triglyceride levels, but patients likely won’t see the same results if they turn to popular—yet unproven—fish oil therapies.

Advances in diabetes care over the past decade haven’t translated into better patient outcomes, researchers at Massachusetts General Hospital have found, with just one in four U.S. adults with the disease meeting treatment goals between 2005 and 2016.

Making the switch from analog insulin to older types of the drug can save patients money, INSIDER reports—but it can also be dangerous.

People who ate the most plant-based foods in a recent Journal of the American Heart Association study were 32% less likely than their counterparts to die from heart disease later down the line.

Overall exposure to ionizing radiation for patients undergoing radiofrequency ablation of AFib is “acceptable” in most cases, according to research published in the American Journal of Cardiology—but obese patients are exposed to a higher dose than their normal-weight counterparts.

In patients with both type 2 diabetes and an elevated cardiovascular risk, metformin lowers the risk of all-cause mortality but does little to protect against CV death, MI or ischemic stroke, a new evaluation of the SAVOR-TIMI 53 trial has found.

Researchers at the Carnegie Institution for Science, Johns Hopkins University and the Mayo Clinic have reportedly leveraged “state-of-the-art” genome editing to track lipoprotein movement in real time, allowing scientists a glimpse into how cholesterol moves, accumulates and gathers to build plaque.

A study published in JAMA Cardiology July 24 suggests high-intensity statin use after MI depends on where patients live in the U.S., with 66% higher use in New England than in the country’s West South Central region.

Young people who used their smartphone five or more hours per day were 43% more likely to be obese than their counterparts with less reported screen time in a recent study presented at the ACC Latin American Conference 2019 in Cartagena, Colombia.